As the year comes to a close, the overall level of global mergers and acquisitions activity in 2024 is expected to be $3.5 ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

INR:3385. members of zerobaseone Innovent Biologics' Phase 3 clinical trial of Sintilimab as first-line treatment for advanced liver cancer reaches primary ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...